Derivation and characterization of a Wilms' tumour cell line, Wit 49

International Journal of Cancer

Volumn 107, Issue 3, 2003, Pages 365-374

  Alami, Jennifer ^a,b   Williams, Bryan R ^c   Yeger, Herman ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Hepatocyte growth factor (HGF); Met; Wilms' tumour cell line

Indexed keywords

BETA CATENIN; COMPLEMENTARY DNA; PROTEIN; RNA; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL FRACTIONATION; ELECTRON MICROSCOPY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; NEPHROBLASTOMA; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BETA CATENIN; CADHERINS; CYTOSKELETAL PROTEINS; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-MET; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; WILMS TUMOR;

EID: 0142027071     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11429     Document Type: Article

References (50)

1. Green DM, D'Angio GJ, Beckwith JB, Breslow NE, Grundy PE, Ritchey ML, Thomas PR. Wilms' tumor. CA Cancer J Clin 1996;46:46-63.
2. Haber DA, Housman DE. Role of the WT1 gene in Wilms' tumour. Cancer Surv 1992;12:105-17.
3. Ehrlich PF. Wilms' tumor: progress to date and future considerations. Expert Rev Anticancer Ther 2001;1:555-64.
4. Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations, Nat Genet 1994;7:91-7.
5. Malkin D, Sexsmith E, Yeger H, Williams BR, Coppes MJ. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor. Cancer Res 1994;54:2077-9.
6. Lahoti C, Thorner P, Malkin D, Yeger H. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome. Am J Pathol 1996;148:1577-89.
7. Wen JG, van Steenbrugge GJ, Egeler RM, Nijman RM. Progress of fundamental research in Wilms' tumor. Urol Res 1997;25:223-30.
8. Nichols KE, Re GG, Yan YX, Garvin AJ, Haber DA. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells. Cancer Res 1995;55:4540-3.
9. Haber DA, Park S, Maheswaran S, Englert C, Re GG, Hazen-Martin DJ, Sens DA, Garvin AJ. WT1-mediated growth suppression of Wilms' tumor cells expressing a WT1 splicing variant. Science 1993;262:2057-9.
10. Marvin MR, Kayton ML, O'Toole KM, Rowe DH, DeRosa C, Kindred A, Trokhan S, Chabot J, Kandel JJ. A metastasizing model of anaplastic human Wilms' tumor in the nude mouse. Eur J Pediatr Surg 1998;8:295-8.
11. Ishiwata I, Ono I, Ishiwata C, Soma M, Nakaguchi T, Ohara K, Hirano M, Ishikawa H. Carcinoembryonic proteins produced by Wilms' tumor cells in vitro and in vivo. Exp Pathol 1991;41:1-9.
12. Alami J, Williams BR, Yeger H, Expression and localization of HGF and met in Wilms' tumours. J Pathol 2002;196:76-84.
13. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y, Nakamura T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 1997;57:3305-13.
14. Al Moustafa AE, Yen L, Benlimame N, Alaoui-Jamali MA. Regulation of E-cadherin/catenin complex patterns by epidermal growth factor receptor modulation in human lung cancer cells. Lung Cancer 2002;37:49-56.
15. Davies G, Jiang WG, Mason MD. HGF/SF modifies the interaction between its receptor c-Met, and the E-cadherin/catenin complex in prostate cancer cells. Int J Mol Med 2001;7:385-8.
16. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci USA 1987;84:6379-83.
17. Kolatsi-Joannou M, Moore R, Winyard PJ, Woolf AS. Expression of hepatocyte growth factor/scatter factor and its receptor, MET, suggests roles in human embryonic organogenesis. Pediatr Res 1997;41:657-65.
18. Isaacs JS, Chiao C, Merrick BA, Selkirk JK, Barrett JC, Weissman BE. p53-dependent p21 induction following gamma-irradiation without concomitant p53 induction in a human peripheral neuroepithelioma cell line. Cancer Res 1997;57:2986-92.
19. Chevalier G, Yeger H, Martinerie C, Laurent M, Alami J, Schofield PN, Perbal B, novH: differential expression in developing kidney and Wilm's tumors. Am J Pathol 1998;152:1563-75.
20. Ellisen LW. Regulation of gene expression by WT1 in development and tumorigenesis. Int J Hematol 2002;76:110-6.
21. Stanhope-Baker P, Williams BR. Identification of connective tissue growth factor as a target of WT1 transcriptional regulation. J Biol Chem 2000;275:38139-50.
22. Graziani A, Gramaglia D, dalla Zonca P, Comoglio PM. Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. J Biol Chem 1993;268:9165-8.
23. Hiscox S, Jiang WG. Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochem Biophys Res Commun 1999;261:406-11.
24. Jiang WG, Hiscox S, Singhrao SK, Puntis MC, Nakamura T, Mansel RE, Hallett MB. Induction of tyrosine phosphorylation and translocation of ezrin by hepatocyte growth factor/scatter factor. Biochem Biophys Res Commun 1995;217:1062-9.
25. Hiscox S, Jiang WG. Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin. J Cell Sci 1999;112 (Pt 18):3081-90.
26. Murphy G, Gavrilovic J. Proteolysis and cell migration: creating a path? Curr Opin Cell Biol 1999;11:614-21.
27. Margulies IM, Hoyhtya M, Evans C, Stracke ML, Liotta LA, Stetler-Stevenson WG. Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomarkers Prev 1992;1:467-74.
28. Nikkari ST, Hoyhtya M, Isola J, Nikkari T, Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol 1996;149:1427-33.
29. Graziani A, Gramaglia D, Cantley LC, Comoglio PM. The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem 1991;266:22087-90.
30. Pritchard-Jones K. The Wilms' tumour gene, WT1, in normal and abnormal nephrogenesis. Pediatr Nephrol 1999;13:620-5.
31. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001;11:143-52.
32. Jeffers M, Rong S, Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 1996;74:505-13.
33. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA 1994;91:4731-5.
34. Zhang YW, Vande Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 2003;88:408-17.
35. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000;19:5582-9.
36. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res 2000;78:31-101.
37. Hamsuna R, Kataoka H, Moriyama T, Itoh H, Seiki M, Koono M. Regulation of matrix metalloproteinase-2 (MMP-2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP-2 expression and activation accompanying up-regulation of membrane type-1 MMP. Int J Cancer 1999;82:274-81.
38. Hiscox S, Jiang WG. Hepatocyte growth factor/scatter factor disrupts epithelial tumour cell-cell adhesion: involvement of beta-catenin. Anticancer Res 1999;19:509-17.
39. Beavon IR. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer 2000;36:1607-20.
40. Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F, Briner J, von Knebel Doeberitz M. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 1999;59:3880-2.
41. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W. Functional interaction of b-catenin with the transcription factor LEF-1. Nature 1996;382:638-42.
42. Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 2002;34:255-68.
43. Van Aken E, De Wever O, Correia da Rocha AS, Mareel M. Defective E-cadherin/catenin complexes in human cancer. Virchows Arch 2001;439:725-51.
44. Nojima D, Nakajima K, Li LC, Franks J, Ribeiro-Filho L, Ishii N, Dahiya R. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma. Mol Carcinog 2001;32:19-27.
45. Katagiri A, Watanabe R, Tomita Y. E-cadherin expression in renal cell cancer and its significance in metastasis and survival. Br J Cancer 1995;71:376-9.
46. Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ, Dinney CP. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 2001;158:735-43.
47. Schulz S, Becker KF, Braungart E, Reichmuth C, Klamt B, Becker I, Atkinson M, Gessler M, Hofler H. Molecular analysis of E-cadherin and cadherin-11 in Wilms' tumours. J Pathol 2000;191:162-9.
48. Maroun CR, Holgado-Madruga M, Royal I, Naujokas MA, Fournier TM, Wong AJ, Park M. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 1999;19:1784-99.
49. Shinohara M, Kodama A, Matozaki T, Fukuhara A, Tachibana K, Nakanishi H, Takai Y. Roles of cell-cell adhesion-dependent tyrosine phosphorylation of Gab-1. J Biol Chem 2001;276:18941-6.
50. Alami J, Williams BRG, Yeger H. Differential expressions of E-cadherin and beta-catenin in primary and metastatic Wilms tumours. Mol Pathol 2003;56:218-25.